DK1407276T3 - Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom - Google Patents

Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom

Info

Publication number
DK1407276T3
DK1407276T3 DK02727576T DK02727576T DK1407276T3 DK 1407276 T3 DK1407276 T3 DK 1407276T3 DK 02727576 T DK02727576 T DK 02727576T DK 02727576 T DK02727576 T DK 02727576T DK 1407276 T3 DK1407276 T3 DK 1407276T3
Authority
DK
Denmark
Prior art keywords
hypoxia
respiratory distress
distress syndrome
cure
alpha
Prior art date
Application number
DK02727576T
Other languages
Danish (da)
English (en)
Inventor
Veerle Compernolle
Peter Carmeliet
Original Assignee
Vlaams Interuniv Inst Biotech
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech, D Collen Res Foundation Vzw filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of DK1407276T3 publication Critical patent/DK1407276T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02727576T 2001-04-24 2002-04-24 Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom DK1407276T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01201481 2001-04-24
EP01203073 2001-08-10
EP02075077 2002-01-11
PCT/EP2002/004479 WO2002086497A2 (fr) 2001-04-24 2002-04-24 Utilisation du facteur 2alpha induit par l'hypoxie pour le traitement du syndrome de detresse respiratoire du nouveau-ne et comme cible pour le traitement de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
DK1407276T3 true DK1407276T3 (da) 2009-12-21

Family

ID=27224281

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02727576T DK1407276T3 (da) 2001-04-24 2002-04-24 Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom

Country Status (8)

Country Link
US (2) US20050043227A1 (fr)
EP (1) EP1407276B1 (fr)
AT (1) ATE446514T1 (fr)
AU (1) AU2002257794B8 (fr)
CA (1) CA2444578C (fr)
DE (1) DE60234100D1 (fr)
DK (1) DK1407276T3 (fr)
WO (1) WO2002086497A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737809B2 (en) * 2000-07-31 2004-05-18 Luxim Corporation Plasma lamp with dielectric waveguide
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005034929A2 (fr) * 2003-10-10 2005-04-21 Fibrogen, Inc. Remodelage et vascularisation de tissus
DE602005024850D1 (de) * 2004-09-24 2010-12-30 Beth Israel Hospital Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
US8030446B2 (en) * 2006-02-10 2011-10-04 Trustees Of Dartmouth College Mutant proline-and-arginine rich peptides and methods for using the same
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
JP2009538915A (ja) * 2006-05-31 2009-11-12 ベス イスラエル ディーコネス メディカル センター 妊娠の合併症を診断および治療する方法
US9345716B2 (en) * 2010-12-10 2016-05-24 Indian Institute Of Technology, Bombay Protein free surfactant composition for pulmonary diseases and a process for preparing the same
LT3043784T (lt) 2013-09-09 2019-08-12 Peloton Therapeutics, Inc. Arilo eteriai ir jų panaudojimo būdai
WO2016144825A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Composés aromatiques, leurs et utilisations
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
EP3267792A4 (fr) * 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions utilisées pour traiter l'hypertension artérielle pulmonaire
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2016198121A1 (fr) 2015-06-12 2016-12-15 Vib Vzw Moyens et méthodes de traitement de l'hypoplasie pulmonaire
WO2017143131A1 (fr) * 2016-02-19 2017-08-24 Cornell University Stabilisation de hif et prévention de maladie pulmonaire néonatale induite par hyperoxie
WO2019006155A1 (fr) 2017-06-28 2019-01-03 Children's Medical Center Corporation Promotion de la croissance pulmonaire
US20210015899A1 (en) * 2018-03-22 2021-01-21 The Children's Medical Center Corporation Methods and compositions relating to lung repair
US20220015730A1 (en) * 2018-11-28 2022-01-20 Koninklijke Philips N.V. Most relevant x-ray image selection for hemodynamic simulation
CN112611877B (zh) * 2020-12-31 2022-09-16 四川大学华西医院 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5695963A (en) * 1997-01-17 1997-12-09 Board Of Regents, The University Of Texas System Endothelial PAS domain protein
AU742365B2 (en) * 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
WO2000009657A2 (fr) * 1998-08-14 2000-02-24 President And Fellows Of Harvard College Methodes de modulation d'une angiogenese

Also Published As

Publication number Publication date
CA2444578C (fr) 2010-12-14
EP1407276B1 (fr) 2009-10-21
AU2002257794B2 (en) 2007-01-25
WO2002086497A3 (fr) 2004-01-08
EP1407276A2 (fr) 2004-04-14
AU2002257794A1 (en) 2002-11-05
US20060205645A1 (en) 2006-09-14
US7307060B2 (en) 2007-12-11
WO2002086497A2 (fr) 2002-10-31
CA2444578A1 (fr) 2002-10-31
AU2002257794B8 (en) 2007-02-15
US20050043227A1 (en) 2005-02-24
ATE446514T1 (de) 2009-11-15
DE60234100D1 (de) 2009-12-03

Similar Documents

Publication Publication Date Title
DK1407276T3 (da) Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom
NO20065487L (no) Modulering av immunglobulinproduksjon og atopiske forstyrrelser
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
ATE439834T1 (de) Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
DE602004031114D1 (de) Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
HUP0204156A2 (hu) Humán interleukin-1 béta elleni rekombináns antitestek
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
JP2008514618A5 (fr)
EA200702616A1 (ru) Дозированная форма для перорального применения
DE60330767D1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
WO2009147248A3 (fr) Séquences d'acides aminés dirigées contre des protéines d'enveloppe d'un virus, et polypeptides comprenant ces séquences destinés au traitement de maladies virales
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EA201000785A1 (ru) Композиции для доставки в легкие
ATE557073T1 (de) Schockbeständige cyanoacrylatmassen
CY1110843T1 (el) Αντισωματα εναντι il-22ra και εταιροι δεσμευσης και μεθοδοι χρησης σε φλεγμονη
WO2010021874A3 (fr) Anticorps anti-il-13 modifiés, compositions, procédés et utilisations
PH12018501025A1 (en) Improved tnf binders
ATE378353T1 (de) Neurotrophe faktoren
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
WO2010142551A8 (fr) Séquences d'acides aminés dirigées contres les récepteurs des cytokines appartenant à la famille il-17
ATE411984T1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
DE50305507D1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees